Dechra Pharmaceuticals PLC — Director's Dealing 2013

Dec 3, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5969U

Dechra Pharmaceuticals PLC

03 December 2013

3 December 2013

Dechra® Pharmaceuticals PLC

("Dechra" or "the Company")

Director / PDMR shareholding

Dechra Pharmaceuticals PLC has been notified that Ian Page, Executive Director, has today exercised SAYE options over 5,316 ordinary shares of 1p each ("Ordinary Shares") at an exercise price of £3.1502 per share.

Following this acquisition, Ian Page's beneficial interest in the Company is 865,067 shares (0.991% of the current issued share capital).

For further information, please contact:

Zoe Goulding, Company Secretary            

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals business.  Its expertise is in the development, manufacturing and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSNKNDQQBDDCBK